Avalon Pharmaceuticals, Inc. (AVRX)

[TITAN]

Avalon Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of cancer therapeutics using AvalonRx technology in the United States. The company offers AVN944, a Phase I clinical development product for the treatment of hematologic and solid tumor cancers. It also engages in preclinical programs to develop inhibitors of the Beta-catenin and Aurora pathways, and discovery programs for Survivin and Myc pathway inhibitors. The company has collaborations with Merck & Co., Inc.; MedImmune, Inc.; Medarex, Inc.; ChemDiv, Inc.; and Novartis Institutes for Biomedical Research, Inc. Avalon Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Germantown, Maryland.